195 related articles for article (PubMed ID: 16377680)
1. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections.
Goldstein EJ; Citron DM; Warren YA; Tyrrell KL; Merriam CV; Fernandez H
Antimicrob Agents Chemother; 2006 Jan; 50(1):148-55. PubMed ID: 16377680
[TBL] [Abstract][Full Text] [Related]
2. Moxifloxacin resistance is prevalent among Bacteroides and Prevotella species in Greece.
Papaparaskevas J; Pantazatou A; Katsandri A; Houhoula DP; Legakis NJ; Tsakris A; Avlamis A
J Antimicrob Chemother; 2008 Jul; 62(1):137-41. PubMed ID: 18385145
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and correlation of clinical outcomes with in vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin.
Goldstein EJ; Solomkin JS; Citron DM; Alder JD
Clin Infect Dis; 2011 Dec; 53(11):1074-80. PubMed ID: 21998288
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of 11 antibiotics against 74 anaerobes isolated from pediatric intra-abdominal infections.
Goldstein EJ; Citron DM; Vaidya SA; Warren YA; Tyrrell KL; Vreni Merriam C; Fernandez H
Anaerobe; 2006 Apr; 12(2):63-6. PubMed ID: 16701615
[TBL] [Abstract][Full Text] [Related]
5. Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra-abdominal pathogens.
Stein GE; Schooley S; Tyrrell KL; Citron DM; Nicolau DP; Goldstein EJ
Anaerobe; 2008 Feb; 14(1):8-12. PubMed ID: 17983770
[TBL] [Abstract][Full Text] [Related]
6. Changing patterns of fluoroquinolone resistance among Bacteroides fragilis group organisms over a 6-year period (1997-2002).
Betriu C; Rodríguez-Avial I; Gómez M; Culebras E; Picazo JJ
Diagn Microbiol Infect Dis; 2005 Nov; 53(3):221-3. PubMed ID: 16243476
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy of moxifloxacin, a new quinolone, in the treatment of experimental intra-abdominal abscesses induced by Bacteroides fragilis in mice.
Thadepalli H; Chuah SK; Gollapudi S
Chemotherapy; 2004 Jun; 50(2):76-80. PubMed ID: 15211081
[TBL] [Abstract][Full Text] [Related]
8. [Bacteroides fragilis group in non-diarrheal human feces and its antimicrobial susceptibility].
Rodríguez E; Gamboa MM; Rodríguez C; Vargas P
Rev Esp Quimioter; 2006 Dec; 19(4):357-62. PubMed ID: 17235405
[TBL] [Abstract][Full Text] [Related]
9. Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli.
Schaumann R; Blatz R; Beer J; Ackermann G; Rodloff AC
J Antimicrob Chemother; 2004 Feb; 53(2):318-24. PubMed ID: 14729746
[TBL] [Abstract][Full Text] [Related]
10. Multicentre survey of the in-vitro activity of seven antimicrobial agents, including ertapenem, against recently isolated Gram-negative anaerobic bacteria in Greece.
Papaparaskevas J; Pantazatou A; Katsandri A; Legakis NJ; Avlamis A;
Clin Microbiol Infect; 2005 Oct; 11(10):820-4. PubMed ID: 16153256
[TBL] [Abstract][Full Text] [Related]
11. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
Hermsen ED; Hovde LB; Sprandel KA; Rodvold KA; Rotschafer JC
Antimicrob Agents Chemother; 2005 Feb; 49(2):685-9. PubMed ID: 15673752
[TBL] [Abstract][Full Text] [Related]
12. Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents.
Goldstein EJ
Clin Infect Dis; 2002 Sep; 35(Suppl 1):S106-11. PubMed ID: 12173118
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the in vitro activity of NVP-LMB415 against clinical anaerobic isolates with emphasis on the Bacteroides fragilis group.
Snydman DR; Jacobus NV; McDermott LA
J Antimicrob Chemother; 2005 Jun; 55(6):1024-8. PubMed ID: 15824092
[TBL] [Abstract][Full Text] [Related]
14. In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
Snydman DR; Jacobus NV; McDermott LA
Antimicrob Agents Chemother; 2008 Dec; 52(12):4492-6. PubMed ID: 18838581
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model.
Noel AR; Bowker KE; Macgowan AP
Antimicrob Agents Chemother; 2005 Oct; 49(10):4234-9. PubMed ID: 16189103
[TBL] [Abstract][Full Text] [Related]
16. [Investigations into the occurrence and the antibiotic susceptibility of gram negative anaerobes of the genera Bacteroides, Prevotella, Porphyromonas and Fusobacterium in specimens obtained from diseased animals].
Even H; Rohde J; Verspohl J; Ryll M; Amtsberg G
Berl Munch Tierarztl Wochenschr; 1998 Oct; 111(10):379-86. PubMed ID: 9818460
[TBL] [Abstract][Full Text] [Related]
17. Determination of moxifloxacin anaerobic susceptibility breakpoints according to the Clinical and Laboratory Standards Institute guidelines.
Ambler J; Rennie R; Poupard J; Koeth L; Stass H; Endermann R; Choudhri S
Diagn Microbiol Infect Dis; 2008 May; 61(1):49-57. PubMed ID: 18342475
[TBL] [Abstract][Full Text] [Related]
18. German multicentre survey of the antibiotic susceptibility of Bacteroides fragilis group and Prevotella species isolated from intra-abdominal infections: results from the PRISMA study.
Seifert H; Dalhoff A;
J Antimicrob Chemother; 2010 Nov; 65(11):2405-10. PubMed ID: 20851813
[TBL] [Abstract][Full Text] [Related]
19. Third Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria.
Wybo I; Piérard D; Verschraegen I; Reynders M; Vandoorslaer K; Claeys G; Delmée M; Glupczynski Y; Gordts B; Ieven M; Melin P; Struelens M; Verhaegen J; Lauwers S
J Antimicrob Chemother; 2007 Jan; 59(1):132-9. PubMed ID: 17095529
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina.
Fernández Canigia L; Castello L; Di Martino A; Greco G; Legaria MC; Litterio M; Predari SC; Rollet R; Rossetti A; Carloni G; Sarchi MI; Bianchini H
Rev Argent Microbiol; 2007; 39(3):156-60. PubMed ID: 17987852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
